Pancreatic Cancer Research

ResearcherAffiliated Hospital of Guizhou Medical UniversityActive in the last 2 years

Xingjun Guo

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-4552-9720; OpenAlex author ID A5013812476. Sources: OpenAlex.

Their work

Papers
33 (first author 6, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
56
Papers, trials and grants by year

2013: 1 paper · 2014: none · 2015: 4 papers · 2016: 4 papers · 2017: 3 papers · 2018: 7 papers · 2019: 6 papers · 2020: 2 papers · 2021: 2 papers · 2022: 2 papers · 2023: 1 paper · 2024: 1 paper

Papers 33

  1. Resistance to gemcitabine is mediated by the circ_0036627/miR-145/S100A16 axis in pancreatic cancer. Co-author DOI 10.1111/jcmm.18444↗
  2. An E3 ubiquitin-proteasome gene signature for predicting prognosis in patients with pancreatic cancer. Co-author DOI 10.3389/fimmu.2023.1332626↗
  3. Hypoxia activated HGF expression in pancreatic stellate cells confers resistance of pancreatic cancer cells to EGFR inhibition. Co-author DOI 10.1016/j.ebiom.2022.104352↗
  4. LncRNA FAM83H-AS1 promotes the malignant progression of pancreatic ductal adenocarcinoma by stabilizing FAM83H mRNA to protect β-catenin from degradation. Co-author DOI 10.1186/s13046-022-02491-2↗
  5. Circ_0092367 Inhibits EMT and Gemcitabine Resistance in Pancreatic Cancer via Regulating the miR-1206/ESRP1 Axis. Co-author DOI 10.3390/genes12111701↗
  6. MiR-146b-3p regulates proliferation of pancreatic cancer cells with stem cell-like properties by targeting MAP3K10. Co-author DOI 10.7150/jca.48418↗
  7. Diagnostic Value of Plasma miR-181b, miR-196a, and miR-210 Combination in Pancreatic Cancer. Co-author DOI 10.1155/2020/6073150↗
  8. Upregulation of METTL14 mediates the elevation of PERP mRNA N6 adenosine methylation promoting the growth and metastasis of pancreatic cancer. Co-author DOI 10.1186/s12943-020-01249-8↗
  9. Danthron suppresses autophagy and sensitizes pancreatic cancer cells to doxorubicin. Co-author DOI 10.1016/j.tiv.2018.10.019↗
  10. Long noncoding RNA LINC01111 suppresses pancreatic cancer aggressiveness by regulating DUSP1 expression via microRNA-3924. Co-author DOI 10.1038/s41419-019-2123-y↗
  11. MicroRNA-137 reduces stemness features of pancreatic cancer cells by targeting KLF12. First author DOI 10.1186/s13046-019-1105-3↗
  12. TFEB-driven autophagy potentiates TGF-β induced migration in pancreatic cancer cells. Co-author DOI 10.1186/s13046-019-1343-4↗
  13. Long noncoding RNA 00976 promotes pancreatic cancer progression through OTUD7B by sponging miR-137 involving EGFR/MAPK pathway. Co-author DOI 10.1186/s13046-019-1388-4↗
  14. The early diagnostic value of combined detection of plasma miR-181b, miR-196a and miR-210 in pancreatic cancer Co-author DOI 10.21203/rs.2.15310/v1↗
  15. Loss of Linc01060 induces pancreatic cancer progression through vinculin-mediated focal adhesion turnover. First author DOI 10.1016/j.canlet.2018.06.015↗
  16. Alantolactone induces apoptosis and improves chemosensitivity of pancreatic cancer cells by impairment of autophagy-lysosome pathway via targeting TFEB. Co-author DOI 10.1016/j.taap.2018.08.003↗
  17. A Five-microRNA Signature for Survival Prognosis in Pancreatic Adenocarcinoma based on TCGA Data. Co-author DOI 10.1038/s41598-018-22493-5↗
  18. HIF-3α Promotes Metastatic Phenotypes in Pancreatic Cancer by Transcriptional Regulation of the RhoC-ROCK1 Signaling Pathway. First author DOI 10.1158/1541-7786.mcr-17-0256↗
  19. Regulatory B cells induced by pancreatic cancer cell-derived interleukin-18 promote immune tolerance via the PD-1/PD-L1 pathway. Co-author DOI 10.18632/oncotarget.22976↗
  20. Three-lncRNA signature is a potential prognostic biomarker for pancreatic adenocarcinoma. Co-author DOI 10.18632/oncotarget.24443↗
  21. Combined inhibition of autophagy and Nrf2 signaling augments bortezomib-induced apoptosis by increasing ROS production and ER stress in pancreatic cancer cells. Co-author DOI 10.7150/ijbs.26776↗
  22. KIF15 promotes pancreatic cancer proliferation via the MEK-ERK signalling pathway. First author DOI 10.1038/bjc.2017.165↗
  23. miR-138-5p suppresses autophagy in pancreatic cancer by targeting SIRT1. First author DOI 10.18632/oncotarget.14360↗
  24. miR-1181 inhibits invasion and proliferation via STAT3 in pancreatic cancer. First author DOI 10.3748/wjg.v23.i9.1594↗
  25. Par3 regulates invasion of pancreatic cancer cells via interaction with Tiam1. Co-author DOI 10.1007/s10238-015-0365-2↗
  26. Circulating myeloid-derived suppressor cells in patients with pancreatic cancer. Co-author DOI 10.1016/s1499-3872(15)60413-1↗
  27. Simultaneous inhibition of the ubiquitin-proteasome system and autophagy enhances apoptosis induced by ER stress aggravators in human pancreatic cancer cells. Co-author DOI 10.1080/15548627.2016.1191722↗
  28. Blocking NF-κB Is Essential for the Immunotherapeutic Effect of Recombinant IL18 in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-15-1144↗
  29. Expression and significance of HIF-1α and HIF-2α in pancreatic cancer. Co-author DOI 10.1007/s11596-015-1521-3↗
  30. MicroRNA-138-5p regulates pancreatic cancer cell growth through targeting FOXC1. Co-author DOI 10.1007/s13402-014-0200-x↗
  31. Synergistic antitumor activity of withaferin A combined with oxaliplatin triggers reactive oxygen species-mediated inactivation of the PI3K/AKT pathway in huma… Co-author DOI 10.1016/j.canlet.2014.11.026↗
  32. Upregulation of miR-181c contributes to chemoresistance in pancreatic cancer by inactivating the Hippo signaling pathway. Co-author DOI 10.18632/oncotarget.6298↗
  33. Balanced Tiam1-rac1 and RhoA drives proliferation and invasion of pancreatic cancer cells. Co-author DOI 10.1158/1541-7786.mcr-12-0632↗

Closest collaborators

The 25 strongest of 56 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Min Wang · 21 shared papers, 2013–2023 · strength 1.86
  2. Renyi Qin · 19 shared papers, 2013–2023 · strength 1.73
  3. Jianxin Jiang · 16 shared papers, 2013–2020 · strength 1.17
  4. Ruizhi He · 12 shared papers, 2016–2022 · strength 0.95
  5. Shutao Pan · 9 shared papers, 2018–2023 · strength 0.90
  6. Xiuhui Shi · 8 shared papers, 2018–2022 · strength 0.70
  7. Yan Zhao · 9 shared papers, 2016–2022 · strength 0.67
  8. Shuo Yu · 4 shared papers, 2018–2024 · strength 0.61
  9. Chunle Zhao · 6 shared papers, 2018–2022 · strength 0.58
  10. Min Zhou · 6 shared papers, 2018–2021 · strength 0.54
  11. Taoyuan Yin · 4 shared papers, 2019–2023 · strength 0.51
  12. Xu Li · 6 shared papers, 2016–2022 · strength 0.47
  13. Li Xu · 5 shared papers, 2013–2021 · strength 0.43
  14. Min Zhou · 4 shared papers, 2018–2022 · strength 0.42
  15. Jun Gong · 3 shared papers, 2020–2023 · strength 0.38
  16. Zhenxiong Zhang · 2 shared papers, 2022–2023 · strength 0.30
  17. Yuhui Liu · 3 shared papers, 2019–2022 · strength 0.29
  18. Chengyi Sun · 4 shared papers, 2015–2019 · strength 0.29
  19. Renyi Qin · 1 shared paper, 2024 · strength 0.28
  20. Chengjian Shi · 5 shared papers, 2015–2020 · strength 0.26
  21. Gongpan Liu · 2 shared papers, 2019–2020 · strength 0.25
  22. Jiangong Li · 2 shared papers, 2019–2020 · strength 0.25
  23. Chao Yu · 3 shared papers, 2015–2019 · strength 0.24
  24. Zhiwei He · 2 shared papers, 2019 · strength 0.21
  25. She Tian · 2 shared papers, 2017–2019 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.